SpikImm has been founded by Truffle Capital and Institut Pasteur. SpikImm’s unique mission is to develop prophylactic mAbs against severe viral diseases in immunocompromised patients. First product is a potent anti-BK virus mAb to protect kidney transplant patients from severe complications caused by BKV, including nephropathies that may result in graft loss.
| Website | https://spikimm.com/ |
| Employees | 6 (2 on RocketReach) |
| Address | 53, Rue de Turbigo, Paris, Île-de-France 75003, FR |
| Industry | Biotechnology Research |
| Keywords | Monoclonal Antibodies, Therapeutic Antibodies, Viral Diseases, Immunology Research, Biotechnology, Immunotherapy, Antiviral Therapy, Pharmaceutical Research, Preventative Medicine, Drug Development, Viral Infection Treatment, Kidney Transplant, Transplant Patients |
| Competitors | Nanell, Ortho Clinical Diagnostics, Biogen, Bio Health Solutions, VaxPro, LLC, NextGen Immuno Therapeutics, Immunosolutions Inc, Novavax, Vaccine Consultancy BV, BIOSPHERE +1 more (view full list) |
Looking for a particular SpikImm employee's phone or email?
SpikImm Questions
Paul Gineste is the CEO of SpikImm.
2 people are employed at SpikImm.
SpikImm is based in Paris, Île-de-France.
Top SpikImm Employees
-
Paul Gineste
Chief Executive Officer at SpikImm
Île-de-France, France2 -
Katia Chohbane-Dardar
Project and Regulatory Affairs Manager at SpikImm
Caluire-et-Cuire, FR
Related Companies
G2Crowd Trusted
300K+
Plugin Users
